You are here

Agency Actions

Declining cases of infection and limitations of the blood test prompt revision
The problem could undercut years of progress
The agency’s current experts will play a role in recruiting new staff
Complete response letter will lead to resubmission of application
The FDA is hoping to get medications to market more quickly
FDA inspections found insanitary conditions
Betrixaban to be launched between August and November
Kappa opioid receptor agonist treats uremic pruritus during hemodialysis
Charges could be as high as $2,000 for those who did not meet PQRS requirements
Commissioner Gottlieb gets tough on schemes to thwart competition